NICE Says Sequential Use Of TNF Inhibitors To Treat RA Is Not Cost Effective
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency, however, recommends use of Abbott's Humira, Wyeth's Enbrel and Johnson & Johnson's Remicade to treat RA.
You may also be interested in...
NICE Affirms Guidance Denying Coverage Of Sequential TNF Inhibitors In RA
Makers of Humira, Enbrel and Remicade had appealed a negative 2006 appraisal, prompting a second look by UK health care agency.
NICE Affirms Guidance Denying Coverage Of Sequential TNF Inhibitors In RA
Makers of Humira, Enbrel and Remicade had appealed a negative 2006 appraisal, prompting a second look by UK health care agency.
NICE Says No To Covering Bristol’s Orencia For Rheumatoid Arthritis
Bristol will file an appeal to the decision within 10 working days, the firm tells “The Pink Sheet” DAILY.